GlassScriptPhysician profile
Joseph J Novack
NPI 1770028573
$2,197.99
in general payments reported to CMS, 2019-2025
27 companies · $857 in 2025
The $857 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $462 · 2022: $246 · 2023: $400 · 2024: $233 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.66 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $570.36 | 2021-2025 | Relistor |
| Lundbeck LLC | $298.65 | 2022-2025 | Vyepti |
| Abbott Laboratories | $228.73 | 2021-2025 | Proclaim |
| Abbvie INC. | $226.00 | 2021-2025 | |
| Mml US, INC. | $128.28 | 2025 | Reactiv8 |
| Boston Scientific Corporation | $87.80 | 2022-2025 | Intracept, General - Pain Management |
| Vertex Pharmaceuticals Incorporated | $64.43 | 2025 | |
| Medtronic, INC. | $61.13 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $59.67 | 2021-2023 | Belbuca |
| Si-Bone, INC. | $55.33 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $43.91 | 2021-2023 | Ztlido |
| Spr Therapeutics, INC | $40.62 | 2025 | Sprint Pns System |
| Ibsa Pharma INC. | $38.10 | 2021-2023 | Tirosint, Licart |
| Arbor Pharmaceuticals, INC. | $36.71 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $35.37 | 2021-2023 | Iovera, Zilretta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $35.00 | 2023 | Kloxxado |
| Grt US Holding, INC. | $25.12 | 2021 | |
| Depuy Synthes Sales INC. | $21.71 | 2023 | Orthovisc |
| Valinor Pharma, LLC | $21.05 | 2025 | Movantik |
| Averitas Pharma INC. | $18.39 | 2025 | Qutenza |
| Fidia Pharma USA INC. | $17.41 | 2025 | Hymovis, Triluron |
| Cumberland Pharmaceuticals, INC. | $15.52 | 2024 | Kristalose |
| Almatica Pharma LLC | $14.95 | 2021 | |
| Lilly USA, LLC | $14.05 | 2021 | |
| Pfizer INC. | $13.99 | 2023 | |
| Allergan, INC. | $13.71 | 2021 | |
| Biodelivery Sciences International, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Novack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.